Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 1.00 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 4/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582972 | 0.90 | FFAR1 (0.82) | FFAR1DGAT1PDK2LPLLIPG | |
| SCHEMBL14857496 | 0.88 | FFAR1 (0.78) | FFAR1DGAT1PDK2LPLLIPG | |
| SCHEMBL30291205 | 0.87 | FFAR1 (0.77) | FFAR1DGAT1JAK2JAK1TYK2 | |
| SCHEMBL9277388 | 0.85 | FFAR1 (0.74) | FFAR1DGAT1JAK2JAK1TYK2 | |
| SCHEMBL15288391 | 0.85 | FFAR1 (0.74) | FFAR1DGAT1LPLLIPGF11 | |
| SCHEMBL15299283 | 0.85 | FFAR1 (0.74) | FFAR1PDK2JAK2JAK1TYK2 | |
| SCHEMBL23414888 | 0.85 | FFAR1 (0.74) | FFAR1DGAT1PDK2LPLLIPG | |
| SCHEMBL14746348 | 0.85 | FFAR1 (0.74) | FFAR1DGAT1LPLLIPGF11 | |
| SCHEMBL9281333 | 0.85 | FFAR1 (0.74) | FFAR1DGAT1LPLLIPGF11 | |
| SCHEMBL4128208 | 0.83 | FFAR1 (0.71) | FFAR1DGAT1PDK2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737443-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4713095-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | AJAX THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | CONVERGENE, LLC | 2025-12-16 | — | — | US | disclosed |
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORP (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011036284-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011036284-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100144783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SIK1, SIK3, SIK2 | FFAR1 2539/4885DGAT1 2055/4885PDK2 606/4885 |
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | JAK2, JAK1, JAK3 | FFAR1 2402/4885DGAT1 3761/4885PDK2 2930/4885 |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | FFAR1 1407/4885DGAT1 3538/4885PDK2 1406/4885 |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | JAK1, MTOR, MOK | FFAR1 1621/4885DGAT1 2009/4885PDK2 147/4885 |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | FFAR1 748/4885DGAT1 3723/4885PDK2 2293/4885 |
| US-20100144783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | CYP3A43, CYP3A4, CYP1A2 | FFAR1 3111/4885DGAT1 4076/4885PDK2 387/4885 |
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | FFAR1 4858/4885DGAT1 2967/4885PDK2 151/4885 |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | BRD4, BRPF3, BICRA | FFAR1 4353/4885DGAT1 2113/4885PDK2 3743/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | FFAR1 4008/4885DGAT1 3874/4885PDK2 3222/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | FFAR1 932/4885DGAT1 988/4885PDK2 1461/4885 |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | FFAR1 438/4885DGAT1 3029/4885PDK2 1005/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | FFAR1 1016/4885DGAT1 1248/4885PDK2 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.